Teicoplanin Injection IP

Trade Name: VacTeico
Available Strength : 200 mg
Available Combination : Teicoplanin Injection IP is a glycopeptide antibiotic effective against serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
Packing : vial
Pack Insert/Leaflet : YES
Therapeutic use : Teicoplanin Injection IP is a glycopeptide antibiotic used to treat serious infections caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus species. It is commonly indicated for infections of the skin and soft tissues, bones and joints, respiratory tract, bloodstream, and heart (endocarditis), especially in patients who cannot tolerate other antibiotics.
Capacity : 100000

Additional Information

The most common markets for this product include the following countries. Please inquire with us if your country or region is not listed:

Asia: Afghanistan, Israel, Jordan, Pakistan, Russia, Saudi Arabia, Singapore, Syria, Philippines, Turkey, Turkmenistan, Uzbekistan, Yemen, Vietnam, Indonesia, Malaysia, Iran, Tajikistan, etc.

Africa: South Africa, Uganda, Nigeria, Ghana, Kenya, Mauritius, Botswana, Egypt, Ethiopia, Libya, Sudan, Congo, Gambia, Ivory Coast , etc.

Africa: South Africa, Uganda, Nigeria, Ghana, Kenya, Mauritius, Botswana, Egypt, Ethiopia, Libya, Sudan, Congo, Gambia, Ivory Coast , etc.

Europe: Austria , Azerbaijan, Belarus, Belgium, Cyprus, Czech Republic, Denmark, France, Georgia, Germany, Hungary, Ireland, Iceland, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Ukraine, United Kingdom (UK) , Latvia, etc.

OCEANIA: Australia, New Zealand, Fiji, etc.